In the advanced non-oncogene addicted NSCLC group, the anti-PD1/PD-L1 inhibitors (Nivolumab, Pembrolizumab, Atezolizumab) were firstly approved as second-line treatment after progression to platinum-doublet chemotherapy [3–5]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.